Standing Order
All companies

Biotech

CRISPR Therapeutics AG

CRSPNASDAQpure-play
Market cap$3.8B
Conviction4/ 5
HQZug, Switzerland
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$39.10

+5.8%

Thesis

CRISPR Therapeutics commercialized one of the first approved CRISPR-based medicines and is extending editing into in vivo and immuno-oncology programs. An approved therapy plus a deep pipeline anchors a leading position in gene editing.

Catalysts

  • Casgevy commercial ramp and patient starts
  • In vivo editing program readouts
  • Cell-therapy and cardiovascular pipeline progress

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 12
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics begins recruiting for Phase 1/2 trial of CTX340 in hypertension (NCT07758634).

  • Nov 5
    Trial readoutClinicalTrials.gov

    CRISPR Therapeutics completes Phase 1 trial NCT05795595 of CTX131 in relapsed/refractory solid tumors

  • Nov 2
    Financial resultsSEC

    CRISPR Therapeutics AG filed 8-K (items 2.02, 9.01) disclosing financial results.

  • Oct 20
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.

  • Oct 19
    LeadershipSEC

    8-K reports item 5.02 leadership change (director/officer departure or appointment).

  • Sep 24
    Trial initiationClinicalTrials.gov

    Long-term follow-up study (NCT06208878) of CRISPR CAR T therapies updated to ENROLLING_BY_INVITATION status.

  • Sep 22
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease.

  • Sep 18
    Trial initiationClinicalTrials.gov

    CRISPR Therapeutics Phase 1 trial NCT07491172 for CTX310 in refractory dyslipidemias begins recruiting.

Not financial advice — research and opinion only. Disclosures